Hiroshi Kuriki
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 27, 2021
Incorporating Unstructured Patient Narratives and Health Insurance Claims Data in Pharmacovigilance: Natural Language Processing Analysis of Patient-Generated Texts About Systemic Lupus Erythematosus.
Journal: JMIR public health and surveillance
Published: April 03, 2021
Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply.
Journal: The New England journal of medicine
Published: February 10, 2021
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Journal: The New England journal of medicine
Published: September 30, 2020
Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40].
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 29, 2019
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Journal: Cancer science
Published: January 16, 2018
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Journal: International journal of hematology
Published: January 11, 2018
Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.
Journal: Japanese journal of clinical oncology
Published: November 23, 2017
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 17, 2017
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: July 11, 2017
Last Updated: 09/26/2026